MedImmune LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 584
- Registration Number
- NCT02054130
- Locations
- ๐บ๐ฆ
Research Site, Zaporizhzhya, Ukraine
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 68
- Registration Number
- NCT02027961
- Locations
- ๐ฎ๐น
Research Site, Napoli, Italy
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 58
- Registration Number
- NCT02013804
- Locations
- ๐บ๐ธ
Research Site, Houston, Texas, United States
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 459
- Registration Number
- NCT02000947
- Locations
- ๐ฌ๐ง
Research Site, Manchester, United Kingdom
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
Suspended
- Conditions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 8760
- Registration Number
- NCT01997450
- Locations
- ๐ฌ๐ง
Research Site, Tooting, United Kingdom
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
Completed
- Conditions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 95000
- Registration Number
- NCT01985997
- Locations
- ๐บ๐ธ
Research Site, Oakland, California, United States
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01878123
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธAltoona Center for Clinical Research, Duncansville, Pennsylvania, United States
๐บ๐ธMetroplex Clinical Research Center, Dallas, Texas, United States
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT01859143
- Locations
- ๐บ๐ธ
Research Site, Portland, Oregon, United States
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 571
- Registration Number
- NCT01843374
- Locations
- ๐ฌ๐ง
Research Site, Wirral, United Kingdom
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01829711
- Locations
- ๐ฌ๐ง
Research Site, Sutton, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath